



2008-12-01

PRESS RELEASE

Oasmia appoints E. Öhman J:or Fondkommission AB as market maker and financial advisor as well as forwards the publication of the interim report

Oasmia Pharmaceutical AB (publ) has appointed E. Öhman J:or Fondkommission AB as market maker for the Oasmia share which is listed on NGM Equity. The purpose is to reduce the difference between bid and ask price and increase the liquidity of the share.

Oasmia has previously started a process to change stock exchange listing to the main list of NASDAQ OMX Stockholm because the company considers NASDAQ OMX to be a more suitable stock exchange for the company's shares. The market maker commitment begins on 1 December 2008 and for a start it applies to the trading on NGM Equity, and if a change of listing to NASDAQ OMX occurs during the term of the agreement, the trading on NASDAQ OMX.

Oasmia has also appointed Öhman as financial advisor in connection to the transfer to NASDAQ OMX and a long-term collaboration concerning capital market activities has been initiated to improve the scope of the company's information to shareholders and other interested parties.

In connection to this Oasmia brings forward the publication of the interim report for the period May – October 2008. The company has previously reported publication on 18 December 2008. The new date of publication is 10 December 2008.

For further information, please contact

Julian Aleksov, CEO, Oasmia Pharmaceutical AB, telephone: +46 (0)18 50 54 40

Concerning liquidity guarantee

Joakim Appeltofft, E. Öhman J:or Fondkommission AB, telephone: +46 (0)40 750 20